ADR news highlights the ongoing challenges to growth in emerging markets, which has led to Diageo Plc (DEO) being reclassified as a neutral buy at Goldman Sachs. The euro zone inflation, however, fell short of estimates and reached its lowest point since December. In contrast, Novo Nordisk (NVO) is promoted to buy from neutral at Swedbank AB, citing several phase-three treatment studies that will help it expand its product offering in the next six to 18 months.